武田制药Takeda Pharmaceutical（TAK）2024财年第四季度及全年财报「NYSE」（英文版）（84页）.pdf

1、Takeda Quarterly Financial ReportFor the Quarter Ended March 31,2025 Table of ContentsFinancial Highlights .3Selected Financial Results .3Revenue by Region .4Recent Developments .5Pipeline and R&D Activities .5Analysis of results of operations,financial position,and cash flow .13Results of Operation

2、s .13Financial Position .20Cash Flows .22Forecast and Management Guidance .23Capital Allocation Policy and Dividends .25Consolidated Financial Statements .26(1)Consolidated Statements of Profit or Loss .26(2)Consolidated Statements of Comprehensive Income .27(3)Consolidated Statements of Financial P

3、osition .28(4)Consolidated Statements of Changes in Equity .30(5)Consolidated Statements of Cash Flows .32(6)Other Information .34Supplementary Information .351.Pipeline .36I.Clinical Development Activities .36II.Recent Progress in stage .44III.Projects removed from pipeline .46IV.Research&Developme

4、nt collaborations/partnering .472.Supplementary Revenue Information .52Revenue by region .52Year to date .52Quarterly .53Product Sales Analysis(vs PY Reported Actual).54Year to date .54Quarterly .56Q4 .56Product Sales Analysis(Reported AER&Core CER Change).58Product Forecast .60Financial Appendix .F

5、inancial HighlightsSelected Financial ResultsTakeda uses certain non-IFRS measures to supplement the analysis of results of operations under International Financial Reporting Standards(IFRS).Refer to Financial Appendix for the definition and reconciliations of non-IFRS Measures.Financial ResultsFor

6、the year ended March 31,AER*CER*(JPY millions)20242025Amount of Change%Change%ChangeRevenue4,263,7624,581,551 317,789 7.5%2.9%Operating profit214,075342,586 128,511 60.0%51.2%Profit before tax52,791175,084 122,293 231.7%206.4%Net profit for the year144,197108,143(36,054)(25.0)%(33.1)%Net profit for